Randomized Trial of Lenalidomide Alone Versus Lenalidomide Plus Rituximab in Patients With Recurrent Follicular Lymphoma: CALGB 50401

Results of study concluded Lenalidomide-Rituximab is more active than lenalidomide alone in recurrent Follicular with similar toxicity.